Ivabradine for Rate Control in Permanent Atrial Fibrillation

• Status: Completed
• Trial end date: 2019-09-17
• Target enrollment: 0
• Participant gender: All

Summary

Ivabradine may be useful as a rate controlling agent in atrial fibrillation without negative effects on hemodynamics and inotropy. The objective in this proof of concept study is to investigate the hypothesis that ivabradine will slow the ventricular response in patients with permanent atrial fibrillation and previously-implanted pacemakers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Yale University

Criteria

Inclusion Criteria:

• Patients with stable blood pressures with permanent atrial fibrillation and implanted pacemaker pacing less than 50% of the time, with or without concomitant beta blocker or calcium channel blocker use

Exclusion Criteria:

• Patients with uncontrolled hypertension will be excluded

• To eliminate confounding effects, patients on Digoxin therapy will be excluded

• Patients on anti-arrhythmic therapy

• Patients with pre-excitation on EKG

• Patients who pace > 50% of the time

• Patients with severe Child-Pugh C hepatic impairment